WHSI yields 2000000.00% · ABBV yields 3.06%● Live data
📍 WHSI pulled ahead of the other in Year 1
Combined, WHSI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WHSI + ABBV for your $10,000?
Wearable Health Solutions, Inc. provides personal response monitoring services and related products to subscribers with medical or age-related conditions in the United States. The company manufactures medical alarm devices that are used to summon help in the event of an emergency. It offers MediPendant, a medical alarm product with speaker in the pendant that enables the user to simply speak and listen directly through the pendant in the event of an emergency; and iHelp, a mobile medical alarm device that utilizes T-Mobile's 2G network to remotely locate a loved one and voice prompts, as well as a dealer portal that enables dealers to manage their own iHelp customer base. The company is also designing and developing iHelp+3G, a wearable biosensor device for health and wellness that operates on 3G network. It offers its products primarily for the elderly and physically disabled, as well as for persons living alone. The company markets its products through its Websites, medipendant.com, and ihelpalarm.com; and wholesalers, as well as distributes its products in Denmark, Ireland, Bermuda, and the People's Republic of China. The company was formerly known as Medical Alarm Concepts Holdings, Inc. and changed its name to Wearable Health Solutions, Inc. in June 2016. Wearable Health Solutions, Inc. was founded in 2008 and is based in Las Vegas, Nevada.
Full WHSI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.